VLT 015
Alternative Names: FAP-2015; VLT-015Latest Information Update: 28 Apr 2024
At a glance
- Originator Valentech
- Class Antipsychotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Schizophrenia in Russia (PO, Tablet)
- 30 Oct 2022 Valentech completes a phase-I clinical trial in Schizophrenia in Russia (PO) (NCT05516121)
- 01 Sep 2022 Valentech announces intention to submit clinical trial application for phase II clinical trials for Schizophrenia (Valentech Email communication, August 2022)